Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
Crossref DOI link: https://doi.org/10.1007/s40262-016-0404-5
Published Online: 2016-05-06
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Khosravan, Reza
Motzer, Robert J.
Fumagalli, Elena
Rini, Brian I.
Funding for this research was provided by:
Pfizer
License valid from 2016-05-06